Tags

Type your tag names separated by a space and hit enter

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
Eur Heart J. 2008 Jul; 29(14):1761-71.EH

Abstract

AIMS

Rimonabant, the first selective cannabinoid type 1 receptor blocker, has been shown to produce weight loss and improvements in several cardiometabolic risk factors over 1 year. We report the 2 year efficacy and tolerability data of rimonabant.

METHODS AND RESULTS

Patients with a body mass index > or =30 or >27 kg/m(2) with treated/untreated hypertension, dyslipidaemia, or both, were randomized to double-blind treatment with placebo, rimonabant 5 or 20 mg once daily plus a calorie-restricted diet for 2 years. Weight loss from baseline to 2 years in the intention-to-treat population was significantly greater with rimonabant 20 mg (mean +/- SD: -5.5 +/- 7.7 kg; P < 0.001) and 5 mg (-2.9 +/- 6.5 kg; P = 0.002) than placebo (-1.2 +/- 6.8 kg). Rimonabant 20 mg produced significantly greater improvements than placebo in waist circumference, high-density lipoprotein cholesterol, triglycerides, fasting glucose and insulin levels, insulin resistance, and metabolic syndrome prevalence. Rimonabant 20 mg produced clinically meaningful improvements in all Impact of Weight on Quality of Life-Lite questionnaire domain scores at 2 years. Rimonabant was generally well tolerated and rates of adverse events, including depressed mood disorders and disturbances were similar to placebo during year 2. Proportions of patients with clinically significant depression (Hospital Anxiety and Depression Scale score >11) were similar in all treatment groups.

CONCLUSION

Rimonabant 20 mg over 2 years promoted clinically relevant and durable weight loss and improvements in cardiometabolic risk factors.

Authors+Show Affiliations

Department of Diabetology, Metabolism, and Clinical Nutrition, Antwerp University Hospital, Wilrijkstraat 10, B-2650 Edegem-Antwerp, Belgium. luc.van.gaal@uza.beNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18417461

Citation

Van Gaal, Luc F., et al. "Long-term Effect of CB1 Blockade With Rimonabant On Cardiometabolic Risk Factors: Two Year Results From the RIO-Europe Study." European Heart Journal, vol. 29, no. 14, 2008, pp. 1761-71.
Van Gaal LF, Scheen AJ, Rissanen AM, et al. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur Heart J. 2008;29(14):1761-71.
Van Gaal, L. F., Scheen, A. J., Rissanen, A. M., Rössner, S., Hanotin, C., & Ziegler, O. (2008). Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. European Heart Journal, 29(14), 1761-71. https://doi.org/10.1093/eurheartj/ehn076
Van Gaal LF, et al. Long-term Effect of CB1 Blockade With Rimonabant On Cardiometabolic Risk Factors: Two Year Results From the RIO-Europe Study. Eur Heart J. 2008;29(14):1761-71. PubMed PMID: 18417461.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. AU - Van Gaal,Luc F, AU - Scheen,André J, AU - Rissanen,Aila M, AU - Rössner,Stephan, AU - Hanotin,Corinne, AU - Ziegler,Olivier, AU - ,, Y1 - 2008/04/15/ PY - 2008/4/18/pubmed PY - 2008/8/30/medline PY - 2008/4/18/entrez SP - 1761 EP - 71 JF - European heart journal JO - Eur. Heart J. VL - 29 IS - 14 N2 - AIMS: Rimonabant, the first selective cannabinoid type 1 receptor blocker, has been shown to produce weight loss and improvements in several cardiometabolic risk factors over 1 year. We report the 2 year efficacy and tolerability data of rimonabant. METHODS AND RESULTS: Patients with a body mass index > or =30 or >27 kg/m(2) with treated/untreated hypertension, dyslipidaemia, or both, were randomized to double-blind treatment with placebo, rimonabant 5 or 20 mg once daily plus a calorie-restricted diet for 2 years. Weight loss from baseline to 2 years in the intention-to-treat population was significantly greater with rimonabant 20 mg (mean +/- SD: -5.5 +/- 7.7 kg; P < 0.001) and 5 mg (-2.9 +/- 6.5 kg; P = 0.002) than placebo (-1.2 +/- 6.8 kg). Rimonabant 20 mg produced significantly greater improvements than placebo in waist circumference, high-density lipoprotein cholesterol, triglycerides, fasting glucose and insulin levels, insulin resistance, and metabolic syndrome prevalence. Rimonabant 20 mg produced clinically meaningful improvements in all Impact of Weight on Quality of Life-Lite questionnaire domain scores at 2 years. Rimonabant was generally well tolerated and rates of adverse events, including depressed mood disorders and disturbances were similar to placebo during year 2. Proportions of patients with clinically significant depression (Hospital Anxiety and Depression Scale score >11) were similar in all treatment groups. CONCLUSION: Rimonabant 20 mg over 2 years promoted clinically relevant and durable weight loss and improvements in cardiometabolic risk factors. SN - 1522-9645 UR - https://www.unboundmedicine.com/medline/citation/18417461/Long_term_effect_of_CB1_blockade_with_rimonabant_on_cardiometabolic_risk_factors:_two_year_results_from_the_RIO_Europe_Study_ L2 - https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehn076 DB - PRIME DP - Unbound Medicine ER -